High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists

. 2016 Oct ; 30 (10) : 2032-2038. [epub] 20160426

Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid27113812

The optimal duration of treatment with vitamin K antagonists (VKA) after venous thromboembolism (VTE) in patients with Philadelphia-negative myeloproliferative neoplasms (MPNs) is uncertain. To tackle this issue, we retrospectively studied 206 patients with MPN-related VTE (deep venous thrombosis of the legs and/or pulmonary embolism). After this index event, we recorded over 695 pt-years 45 recurrences, venous in 36 cases, with an incidence rate (IR) of 6.5 per 100 pt-years (95% confidence interval (CI): 4.9-8.6). One hundred fifty-five patients received VKA; the IR of recurrent thrombosis per 100 pt-years was 4.7 (95% CI: 2.8-7.3) on VKA and 8.9 (95% CI: 5.7-13.2) off VKA (P=0.03). In patients receiving VKA, the IR of recurrent thrombosis per 100 pt-years was 5.3 (95% CI: 3.2-8.4) among 108 patients on long-term VKA and 12.8 (95% CI: 7.3-20.7) after discontinuation among the 47 who ceased treatment (P=0.008), with a doubled risk of recurrence after stopping VKA (hazard ratio: 2.21, 95% CI: 1.19-5.30). The IR of major bleeding per 100 pt-years was 2.4 (95%: CI: 1.1-4.5) on VKA and 0.7 (95% CI: 0.08-2.5) off VKA (P=0.08). In conclusion, in MPN patients with VTE recurrent thrombosis is significantly reduced by VKA and caution should be adopted in discontinuation; however, the incidence of recurrence on treatment remains high, calling for clinical trials aimed to improve prophylaxis in this setting.

Zobrazit více v PubMed

Ann Hematol. 2014 Dec;93(12 ):1953-63 PubMed

Haematologica. 2007 Feb;92(2):199-205 PubMed

Thromb Haemost. 2000 May;83(5):657-60 PubMed

Leukemia. 2008 Jan;22(1):14-22 PubMed

Chest. 2012 Feb;141(2 Suppl):e419S-94S PubMed

Blood. 2013 Mar 7;121(10 ):1720-8 PubMed

J Clin Oncol. 2011 Feb 20;29(6):761-70 PubMed

Best Pract Res Clin Haematol. 2012 Sep;25(3):235-42 PubMed

Blood. 2013 Mar 7;121(10):1701-11 PubMed

N Engl J Med. 2013 Oct 10;369(15):1406-15 PubMed

N Engl J Med. 2004 Jan 8;350(2):114-24 PubMed

J Intern Med. 2007 Sep;262(3):341-50 PubMed

Am J Hematol. 2015 Feb;90(2):162-73 PubMed

Blood. 2014 Sep 18;124(12 ):1968-75 PubMed

J Thromb Haemost. 2007 Apr;5(4):692-9 PubMed

N Engl J Med. 2010 Dec 23;363(26):2499-510 PubMed

Ann Hematol. 2015 Jun;94(6):911-8 PubMed

J Thromb Haemost. 2005 Apr;3(4):692-4 PubMed

N Engl J Med. 2013 Aug 29;369(9):799-808 PubMed

N Engl J Med. 2013 Jan 3;368(1):22-33 PubMed

BMJ. 2011 May 24;342:d3036 PubMed

Haematologica. 2008 Mar;93(3):372-80 PubMed

N Engl J Med. 2012 Apr 5;366(14):1287-97 PubMed

J Clin Oncol. 2005 Apr 1;23(10):2224-32 PubMed

N Engl J Med. 2005 Jul 7;353(1):33-45 PubMed

Thromb Res. 2014 Aug;134(2):251-4 PubMed

Blood. 2016 Feb 11;127(6):696-702 PubMed

Najít záznam

Citační ukazatele

    Možnosti archivace